Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial by Altorki, Nasser K, Prof, McGraw, Timothy E, Prof, Borczuk, Alain C, Prof, Saxena, Ashish, MD, Port, Jeffrey L, Prof, Stiles, Brendon M, MD, Lee, Benjamin E, MD, Sanfilippo, Nicholas J, MD, Scheff, Ronald J, MD, Pua, Bradley B, MD, Gruden, James F, Prof, Christos, Paul J, PhD, Spinelli, Cathy, BS, Gakuria, Joyce, MPH, Uppal, Manik, MD, Binder, Bhavneet, MS, Elemento, Olivier, Prof, Ballman, Karla V, Prof, Formenti, Silvia C, Prof

Get full text

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial by DeMatteo, Ronald P, Prof, Ballman, Karla V, PhD, Antonescu, Cristina R, MD, Maki, Robert G, MD, Pisters, Peter WT, Prof, Demetri, George D, MD, Blackstein, Martin E, MD, Blanke, Charles D, Prof, von Mehren, Margaret, MD, Brennan, Murray F, Prof, Patel, Shreyaskumar, Prof, McCarter, Martin D, MD, Polikoff, Jonathan A, MD, Tan, Benjamin R, MD, Owzar, Kouros, PhD

Get full text